piomat
Posted by piomat
May 4, 2021
May 4, 2021

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer

CatalYm Appoints Industry Leader Dr. Phil L’Huillier as Chief Executive Officer Munich,...

Read More
piomat
Posted by piomat
March 1, 2021
March 1, 2021

CatalYm Announces Key Management and Board Changes

CatalYm Announces Key Management and Board Changes Dr. Manfred Ruediger steps down...

Read More
piomat
Posted by piomat
January 28, 2021
January 28, 2021

CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002 to Treat Patients with Checkpoint-Inhibitor Refractory Cancer

CatalYm Starts First-in-Human Phase I Clinical Trial with GDF-15 Neutralizing Antibody CTL-002...

Read More
piomat
Posted by piomat
November 10, 2020
November 10, 2020

CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patients

CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for...

Read More
piomat
Posted by piomat
June 18, 2020
June 18, 2020

CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of Cancer at the AACR Annual Meeting 2020

CatalYm to Present Data on Targeting Novel Checkpoint GDF-15 for Immunotherapy of...

Read More
WordPress Cookie Notice by Real Cookie Banner